Download App

Log in to access Online Inquiry
Company Overview More
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
CEO: Ji Ph.D., Henry H.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

SRNE Sorrento Therapeutics

1.590+0.010+0.63%
Close 05/20 20:00 ET
1.570-0.02-1.26%
Post Mkt Price 05/20 19:59 ET
High
1.630
Open
1.620
Turnover
8.11M
Low
1.490
Pre Close
1.580
Volume
5.19M
Market Cap
618.42M
P/E(TTM)
Loss
52wk High
11.070
Shares
388.95M
P/E(Static)
Loss
52wk Low
1.150
Float Cap
582.72M
Bid/Ask %
33.33%
Historical High
749.999
Shs Float
366.49M
Volume Ratio
0.57
Historical Low
0.500
Dividend TTM
--
Div Yield TTM
--
P/B
2.73
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.42%
Amplitude
8.86%
Avg Price
1.562
Lot Size
1
Float Cap
582.72M
Bid/Ask %
33.33%
Historical High
749.999
Shs Float
366.49M
Volume Ratio
0.57
Historical Low
0.500
Dividend TTM
--
P/B
2.73
Dividend LFY
--
Turnover Ratio
1.42%
Amplitude
8.86%
Avg Price
1.562
Lot Size
1
Price Forecast

No Data

News

Comment